1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49.
2.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 2021; 18: 493-502.
3.
Domagała-Haduch M, Robek A, Wnuk J, Michalecki Ł, Gisterek I. Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas. Contemp Oncol (Pozn) 2023; 27: 10-13.
4.
Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of pancreatic cancer in primary care: a systematic review. Pancreas 2016; 45: 814-818.
5.
Adamczuk-Nurzyńska A, Nurzyński P, Brzozowska M, Jewczak M, Śliwczyński A. Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer. Contemp Oncol (Pozn) 2025; 29: 171-178.
6.
Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 2023; 164: 752-765.
7.
Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, et al. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep 2020; 10: 1332.
8.
Van Manen L, Groen JV, Putter H, Vahrmeijer AL, Swijnenburg RJ, Bonsing BA, et al. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers 2020; 25: 186-193.
9.
Pęczek P, Gajda M, Rutkowski K, Fudalej M, Deptała A, Badowska- Kozakiewicz AM. Cancer-associated inflammation: pathophysiology and clinical significance. J Cancer Res Clin Oncol 2023; 149: 2657-2672.
10.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019; 51: 27-41.
11.
Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol 2024; 17: 40.
12.
Kim HJ, Lee SY, Kim DS, Kang EJ, Kim JS, Choi YJ, et al. Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean J Intern Med 2020; 35: 171-184.
13.
Johnston KM, Lakzadeh P, Donato BMK, Szabo SM. Methods of sample size calculation in descriptive retrospective burden of illness studies. BMC Med Res Methodol 2019; 19: 9.
14.
International Council for Harmonisation. ICH E6(R2): integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice. Available from: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf (accessed 01.06.2025).
15.
Polish Society of Pathologists. Guidelines for Histopathological Diagnosis of Neoplasms. Warsaw: Polish Society of Pathologists. Available from: https://pol-pat.pl/pliki/files/raporty.pdf (accessed 01.06.2025).
16.
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 987-1002.
17.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19: 439-457.
18.
World Health O. International statistical classification of diseases and related health problems, 10th revision (5th ed.). World Health Organization, Geneva 2015. Available from: https://icd.who.int/browse10/content/statichtml/icd10volume2_en_2016.pdf (accessed 01.06.2025).
19.
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-349.
20.
Riley L, Guthold R, Cowan M, Savin S, Bhatti L, Armstrong T, et al. The World Health Organization STEPwise approach to noncommunicable disease risk-factor surveillance: methods, challenges, and opportunities. Am J Public Health 2016; 106: 74-78.
21.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22.
Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018; 25: 845-847.
23.
Shen H, Zuo F. Prognostic role of systemic inflammation response index (SIRI) in patients with pancreatic cancer: a meta-analysis. Front Oncol 2024; 14: 1465279.
24.
Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil- lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015; 236: 297-304.
25.
Neumann CCM, Schneider F, Hilfenhaus G, Vecchione L, Felsenstein M, Ihlow J, et al. Inflammation-based prognostic scores in pancreatic cancer patients-a single-center analysis of 1294 patients within the last decade. Cancers (Basel) 2023; 15: 2367.
26.
Worapongpaiboon R, Siranart N, Pajareya P, Phutinart S. Inflammatory markers in predicting survival in pancreatic cancer: a systematic review and meta-analysis. Pancreatology 2025; 25: 385-395.
27.
Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, et al. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep 2020; 10: 18758.
28.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37: S81-90.
29.
Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025; 82: e212-e316.
30.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19: 439-457.
31.
Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.
32.
Guven DC, Sahin TK, Erul E, Rizzo A, Ricci AD, Aksoy S, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta- analysis. Front Mol Biosci 2022; 9: 1039121.
33.
Ye J, Matsuda Y. Hyperbilirubinemia in gemcitabine plus nab-paclitaxel – treated patients with pancreatic cancer. Dig Med Res 2020; 3.
34.
Lee CH, Lin C, Wang CY, Huang TC, Wu YY, Chien WC, et al. Premorbid BMI as a prognostic factor in small-cell lung cancer-a single institute experience. Oncotarget 2018; 9: 24642-24652.
35.
Shrotriya S, Walsh D, Nowacki AS, Lorton C, Aktas A, Hullihen B, et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS One 2018; 13: e0202555.
36.
Balaban DV, Marin FS, Manucu G, Zoican A, Ciochina M, Mina V, et al. Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer. World J Clin Oncol 2022; 13: 630-640.
37.
Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 2013; 54: 643-649.
38.
Chua DTT, Sham JST, Choy DTK. Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone. Cancer 2004; 101: 307-316.
39.
Domínguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, et al. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008; 32: 1051-1056.
40.
Li Y, Wang J, Wang H, Zhang S, Wei Y, Liu S. The interplay between inflammation and stromal components in pancreatic cancer. Front Immunol 2022; 13: 850093.
41.
Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 2016; 122: 2158-2167.
42.
Li S, Xu H, Wang W, Gao H, Li H, Zhang S, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res 2019; 11: 3327-3337.
43.
Kim JS, Choi M, Kim SH, Hwang HK, Lee WJ, Kang CM. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Pancreatology 2022; 22: 987-993.
44.
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014; 20: 6212-6222.
45.
Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune- inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 2017; 15: 221.
46.
Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer 2018; 9: 3295-3302.
47.
Shui Y, Li M, Su J, Chen M, Gu X, Guo W. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging (Albany NY) 2021; 13: 20585-20597.
48.
Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 2014; 110: 183-188.
49.
Kim ES, Kim SY, Moon A. C-reactive protein signaling pathways in tumor progression. Biomol Ther (Seoul) 2023; 31: 473-483.
50.
Badowska-Kozakiewicz A, Fudalej M, Kwaśniewska D, Durlik M, Nasierowska-Guttmejer A, Mormul A, et al. Diabetes mellitus and pancreatic ductal adenocarcinoma-prevalence, clinicopathological variables, and clinical outcomes. Cancers 2022; 14: 2840.
51.
Huang JB, Zhou ZY, Lu J, Zhu JY, Lai B, Mao SX, et al. Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy. Front Immunol 2024; 15: 1471399.
52.
Aoyama T, Maezawa Y, Hashimoto I, Esashi R, Yamamoto S, Kazama K, et al. Inflammatory burden index is an independent prognostic factor for esophageal cancer patients who receive curative treatment. In Vivo 2024; 38: 2928-2934.
53.
Li W, Zhao D, Li W. Inflammatory burden index predicts long term mortality in a nationally representative population from NHANES. Sci Rep 2025; 15: 25034.
